跳转至内容
Merck

A1010

Sigma-Aldrich

氧化砷(III)

ReagentPlus®, ≥99.0%

别名:

三氧化二砷, 亚砷酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
As2O3
CAS号:
分子量:
197.84
EC號碼:
MDL號碼:
分類程式碼代碼:
12171602
PubChem物質ID:
NACRES:
NA.55

蒸汽壓力

0 hPa ( 66 °C)

產品線

ReagentPlus®

化驗

≥99.0%

形狀

powder

儲存溫度

room temp

SMILES 字串

O=[As]O[As]=O

InChI

1S/As2O3/c3-1-5-2-4

InChI 密鑰

IKWTVSLWAPBBKU-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

氧化砷(III),也称为三氧化二砷,是一种可用作合成多种砷基化合物原料的两性氧化物。它可用于使玻璃和搪瓷脱色。它在治疗急性早幼粒细胞白血病(APL)中的功效已被研究。

應用

氧化砷(III)已被用于一项详细研究三氧化二砷与γ辐射结合以阐明血红蛋白(Hb)效果的研究中。

生化/生理作用

针对急性早幼粒细胞白血病(APL)的强效剂。引起皮肤癌、肺癌和膀胱癌。

法律資訊

ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Skin Corr. 1B - STOT RE 1

標靶器官

Respiratory system,Cardio-vascular system,Gastrointestinal tract

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Wilson H Miller et al.
Cancer research, 62(14), 3893-3903 (2002-07-19)
Arsenic trioxide has shown substantial efficacy in treating both newly diagnosed and relapsed patients with acute promyelocytic leukemia (APL). As a single agent, it induces complete remissions, causing few adverse effects and only minimal myelosuppression. These successes have prompted investigations
Combined effect of arsenic trioxide and radiation on physical properties of hemoglobin biopolymer.
Saad-El-Din AA, et al.
Journal of Radiation Research and Applied Sciences, 7(2), 411-416 (2014)
E Lengfelder et al.
Leukemia, 26(3), 433-442 (2011-09-10)
Arsenic trioxide (ATO) is presently the most active single agent in the treatment of acute promyelocytic leukemia (APL). This review provides insights into the mode of action and the pharmacological properties of ATO, and summarizes the most relevant results of
Dikshith TSS
Handbook of Chemicals and Safety, 92-92 (1992)
Z X Shen et al.
Blood, 89(9), 3354-3360 (1997-05-01)
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15 APL patients at relapse after all-trans retinoic acid (ATRA) induced and chemotherapy maintained complete remission (CR). As2O3 was administered intravenously at

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门